- ►glucagon.com [PDF] JE Ayala, DP Bracy, T Hansotia, G Flock, Y … - Diabetes, 2008 - Am Diabetes Assoc RESULTS—Compared with wild-type mice, chow and high fat–fed DIRKO mice
exhibited decreased fat and muscle mass associated with increased energy
expenditure and ambulatory activity. Clamp rates of glucose infusion (GIR), ... Cited by 9 - Related articles - BL Direct - All 5 versions
R Jorde, HL Waldum, PG Burhol, I Lygren, TB … - Scandinavian journal of gastroenterology, 1981 - ncbi.nlm.nih.gov Six healthy men were given a standard breakfast, one day with and another day
without a 2-h 100 micrograms/h somatostatin infusion. During the somatostatin
infusion the meal-induced responses of plasma GIP and serum insulin were ... Cited by 5 - Related articles
- ►diabetesjournals.org G Flock, LL Baggio, C Longuet, DJ Drucker - Diabetes, 2007 - Am Diabetes Assoc RESULTS—Vildagliptin had no significant effect on food intake, energy
expenditure, body composition, body weight gain, or insulin sensitivity in WT or
DIRKO mice. However, glycemic excursion after oral glucose challenge was ... Cited by 12 - Related articles - BL Direct - All 4 versions
M Salera, L Pironi, P Giacomoni, S Venturi, M … - Digestion, 1982 - content.karger.com The effect of intravenous somatostatin infusion on circulating gastric
inhibitory polypeptide (GIP), insulin, glucagon and on blood glucose was
investigated in 7 healthy volunteers in the fasting state and during the ... Cited by 6 - Related articles - All 4 versions
B Ahren, S Lindskog, G Van Dijk, AJ Scheurink … - Endocrine research, 1995 - ncbi.nlm.nih.gov The truncated glucagon-like peptide-1 (GLP-1(7-36)amide or GLP-1) stimulates
insulin secretion, enhances glucose elimination and is of potential interest in
diabetes treatment. We studied the hypoglycemic action of GLP-1 in normal ... Cited by 7 - Related articles - BL Direct - All 3 versions
- ►endojournals.org K Azuma, Z Radikova, J Mancino, FGS Toledo, … - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Objective: Pharmacological inhibition with the dipeptidyl peptidase 4 (DPP-4)
inhibitor vildagliptin prolongs the action of endogenously secreted incretin
hormones leading to improved glycemic control in patients with type 2 ... Cited by 24 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org BJ Lamont, DJ Drucker - Diabetes, 2008 - Am Diabetes Assoc RESULTS AND CONCLUSIONS— Mice treated with vehicle alone or DA-GIP exhibited
progressive weight gain, whereas treatment with Ex-4 or DPP-4i prevented weight
gain. Although Ex-4 improved oral glucose tolerance and insulin-to-glucose ... Cited by 17 - Related articles - BL Direct - All 5 versions
G Van Dijk, S Lindskog, JJ Holst, AB Steffens, … - American Journal of Physiology- Endocrinology And …, 1996 - Am Physiological Soc Van Dijk, Gertjan, Stefan Lindskog, Jens J. Holst, Anton B. Steffens, and Bo
Ahrh. Effects of glucagon-like peptide- on glucose turnover in rats. Am. J.
Physiol. 270 (EndocrinoZ. Metab. 33): El015-El021, 1996.-The influ- Cited by 17 - Related articles - BL Direct - All 4 versions
H Duez, AC Smith, C Xiao, A Giacca, L Szeto, … - glucagon.com Page 1. 1 Acute DPP-4 Inhibition rapidly Enhances Insulin-mediated
Suppression of Endogenous Glucose Production in Mice Hélène ... Related articles - View as HTML
- ►glucagon.com [PDF] H Duez, AC Smith, C Xiao, A Giacca, L Szeto, … - Endocrinology, 2009 - Endocrine Soc Pharmacological approaches that enhance incretin action for the treatment of
type 2 diabetes mellitus have recently been developed, ie. injectable
glucagon-like peptide-1 receptor (GLP-1R) agonists with prolonged plasma ... Related articles - All 3 versions
